February 23-26, 2024, Washington, DC, USA

American Academy of Allergy Asthma & Immunology (AAAAI)

February 24-27, 2023, San Antonio, TX

American Academy of Allergy Asthma & Immunology (AAAAI)

American Academy of Allergy Asthma & Immunology (AAAAI)

thumb icon

Efficacy of remibrutinib in patients with chronic spontaneous urticaria with or without prior exposure to biologics in the Phase 3 REMIX-1 and REMIX-2 studies

G. Mosnaim, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, M. Maurer, M. Metz, S. Saini,
G. Sussman, S. Haemmerle, K. Lheritier, El-D. Martzloff, N. Seko, P. Wang, S. Gogate
Abstract Poster
thumb icon

Remibrutinib monotherapy reduced rescue medication in chronic spontaneous urticaria patients: Findings from a Phase 2b extension study

L. Clore, W. Carr, J. Tillinghast, V. Jain, J. Reed, P. Staubach, K. Lheritier, P. Walsh,
I. Nikolaev, S. Haemmerle, A.M. Giménez-Arnau
Abstract Poster
thumb icon

Remibrutinib treatment has no impact on mean blood cell counts in patients with chronic spontaneous urticaria: Results from Phase 2, 52-week extension study

A. Greiner, V. Jain, A.M Giménez-Arnau, J. Tillinghast, K. Lheritier, P. Walsh, S. Haemmerle, A. Zharkov, R. Snyder
Abstract Poster
thumb icon

Remibrutinib treatment did not impact mean total serum immunoglobulin levels or infection rates in patients with chronic spontaneous urticaria: Phase 2b study results

W. Carr, A.M. Giménez-Arnau, K. Lheritier, S. Haemmerle, A. Zharkov, S. Dahale,
K. Hayama, R. Snyder
Abstract Poster
thumb icon

Frequency of angioedema in chronic spontaneous urticaria patients: Report from the Urticaria Voices study

J.A. Bernstein, T.A. Winders, M-M. Balp, P. Saraswat, J. McCarthy, T. Raftery, M. Kuruvilla,
K. Weller
Abstract Poster
thumb icon

Time to relapse during treatment-free follow-up without remibrutinib in patients with chronic spontaneous urticaria: Subgroup analysis by baseline immunoglobulin-E levels and chronic urticaria index status from a Phase 2b extension study

A. Greiner, V. Jain, A.M. Giménez-Arnau, J. Tillinghast, K. Lheritier, S. Haemmerle, P. Walsh, I. Nikolaev, R. Snyder
Abstract Oral Presentation
thumb icon

Burden of angioedema among patients with chronic spontaneous urticaria in the United States

D. Patil, M-M. Balp, J. Rodrigues, R.K. Kohli, K. Krupsky, B.L. Balkaran, S. Gupta,
B.J. Williams, W. Soong
Abstract Poster
thumb icon

Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from the 52-week Phase 2b extension study

W. Carr, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, M. Wells, A. Zharkov, S. Hugot, A.M. Giménez-Arnau
Abstract Oral presentation
thumb icon

Remibrutinib improves chronic spontaneous urticaria in patients irrespective of previous anti-Ige treatment: Results from a Phase 2b study

A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev, A.M. Giménez-Arnau, M. Maurer
Abstract Poster
thumb icon

Efficacy and safety of ligelizumab in chronic spontaneous urticaria: Results from the Phase-3 pivotal trials

L.F. Ensina, J.A. Bernstein, G. Sussman, M. Maurer, A.M. Giménez-Arnau, S. Saini, V. Varanasi, A. Barve, E. Hua, M. Patekar, T. Severin
Abstract Poster
Novartis logo
Cookie Settings
© Copyright 2024 Novartis Pharma AG